$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2016 Q1 Form 10-K Financial Statement

#000114420416086932 Filed on March 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $830.0K $570.0K $3.590M
YoY Change -13.54% -44.66% 35.47%
% of Gross Profit
Research & Development $990.0K $830.0K $4.949M
YoY Change -20.48% -49.39% 3.71%
% of Gross Profit
Depreciation & Amortization $16.00K $20.00K $87.00K
YoY Change -20.0% -33.33% -17.92%
% of Gross Profit
Operating Expenses $1.810M $1.400M $4.949M
YoY Change -17.91% -47.57% -33.31%
Operating Profit -$1.812M -$8.536M
YoY Change -17.82% 15.02%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $20.00K $10.00K $50.00K
YoY Change -166.67% -116.67% -102.73%
Pretax Income -$1.790M -$1.380M -$2.842M
YoY Change -20.09% -49.45% -24.99%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.790M -$1.380M -$8.488M
YoY Change -19.95% -49.45% -8.2%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$95.98K -$74.35K -$461.2K
COMMON SHARES
Basic Shares Outstanding 18.65M shares 18.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.95M $15.96M $15.96M
YoY Change -39.34% 86.89% 86.89%
Cash & Equivalents $2.213M $428.0K $430.0K
Short-Term Investments $10.73M $15.53M $15.53M
Other Short-Term Assets $80.00K $70.00K $70.00K
YoY Change 100.0% 133.33% 133.33%
Inventory
Prepaid Expenses
Receivables $480.0K $760.0K $760.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.51M $16.79M $16.79M
YoY Change -38.81% 74.91% 75.26%
LONG-TERM ASSETS
Property, Plant & Equipment $281.0K $271.0K $270.0K
YoY Change -3.1% -13.42% -12.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $304.0K $292.0K $20.00K
YoY Change 1420.0% -12.31% 0.0%
Total Long-Term Assets $304.0K $292.0K $290.0K
YoY Change -1.62% -6.71% -12.12%
TOTAL ASSETS
Total Short-Term Assets $13.51M $16.79M $16.79M
Total Long-Term Assets $304.0K $292.0K $290.0K
Total Assets $13.81M $17.08M $17.08M
YoY Change -38.29% 72.33% 72.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $281.0K $1.169M $1.170M
YoY Change -69.52% -24.19% -24.03%
Accrued Expenses $675.0K $1.500M $1.500M
YoY Change -57.03% 11.36% 11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.242M $2.952M $2.950M
YoY Change -54.44% -5.17% -5.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.242M $2.952M $2.950M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.240M $2.952M $2.950M
YoY Change -54.51% -8.78% -8.95%
SHAREHOLDERS EQUITY
Retained Earnings -$71.93M -$70.14M
YoY Change 12.59% 13.77%
Common Stock $11.00K $84.27M
YoY Change -99.99% 23.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.57M $14.13M $14.13M
YoY Change
Total Liabilities & Shareholders Equity $13.81M $17.08M $17.08M
YoY Change -38.31% 72.33% 72.35%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$1.790M -$1.380M -$8.488M
YoY Change -19.95% -49.45% -8.2%
Depreciation, Depletion And Amortization $16.00K $20.00K $87.00K
YoY Change -20.0% -33.33% -17.92%
Cash From Operating Activities -$2.980M -$1.290M -$7.410M
YoY Change 53.85% -35.82% 65.14%
INVESTING ACTIVITIES
Capital Expenditures $26.00K -$20.00K $45.00K
YoY Change -71.43% -72.05%
Acquisitions
YoY Change
Other Investing Activities $4.790M $910.0K -$11.24M
YoY Change -135.3% -133.83% 162.0%
Cash From Investing Activities $4.770M $900.0K -$11.28M
YoY Change -135.16% -132.61% 153.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 110.0K 14.87M
YoY Change -100.0% 120.0% 53.54%
NET CHANGE
Cash From Operating Activities -2.980M -1.290M -7.410M
Cash From Investing Activities 4.770M 900.0K -11.28M
Cash From Financing Activities 0.000 110.0K 14.87M
Net Change In Cash 1.790M -280.0K -3.820M
YoY Change -336.46% -94.07% -610.7%
FREE CASH FLOW
Cash From Operating Activities -$2.980M -$1.290M -$7.410M
Capital Expenditures $26.00K -$20.00K $45.00K
Free Cash Flow -$3.006M -$1.270M -$7.455M
YoY Change 55.19% -34.54% 60.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Trading Symbol
TradingSymbol
BCLI
CY2015Q2 dei Entity Public Float
EntityPublicFloat
57972791 USD
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18654040 shares
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4251000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
428000 USD
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
15527000 USD
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
4290000 USD
CY2015Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
759000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
74000 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
16788000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4949000 USD
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13662758 shares
CY2015Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
21000 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
20000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3823000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
748000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3503000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9554000 USD
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
12409000 USD
CY2014 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
84258000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68317000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70141000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61653000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
14128000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
6675000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17080000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9911000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4772000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3587000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2649000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-8488000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-9246000 USD
CY2015 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.46
CY2014 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.68
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18405610 shares
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-7421000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
2739000 USD
CY2014 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
198000 USD
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1024000 USD
CY2014 bcli Stock Issued During Period For Private Placement Value
StockIssuedDuringPeriodForPrivatePlacementValue
9554000 USD
CY2014 bcli Stock Issued During Period Value Issued For Warrants Exchange
StockIssuedDuringPeriodValueIssuedForWarrantsExchange
1633000 USD
CY2014 bcli Adjustments To Additional Paid In Capital Warrant Redemption In Cash
AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash
42000 USD
CY2014 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
701000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000 USD
CY2015 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
87000 USD
CY2014 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
106000 USD
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7000 USD
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1743000 USD
CY2015 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
212000 USD
CY2014 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
467000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-373000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1314000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7408000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4487000 USD
CY2014 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1024000 USD
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
198000 USD
CY2014 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
93000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000 USD
CY2015 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
11237000 USD
CY2014 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
4290000 USD
CY2015 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
1000 USD
CY2014 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
-1000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11283000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4450000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14868000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9685000 USD
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015 bcli Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05 pure
CY2015 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2015 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03 pure
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18643288 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18643288 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15281497 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15281497 shares
CY2015 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
CY2014 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
600000 USD
CY2015 us-gaap Stock Issued1
StockIssued1
0 USD
CY2014 us-gaap Stock Issued1
StockIssued1
1633000 USD
CY2015 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
-130000 USD
CY2014 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
-42000 USD
CY2015 bcli Noncash Financing Activities
NoncashFinancingActivities
130000 USD
CY2014 bcli Noncash Financing Activities
NoncashFinancingActivities
1675000 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2459000 USD
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
731000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
57000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
43000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
316000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
107000 USD
CY2015 bcli Research And Development Cost
ResearchAndDevelopmentCost
6335000 USD
CY2014 bcli Research And Development Cost
ResearchAndDevelopmentCost
6116000 USD
CY2015 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1386000 USD
CY2015 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
108000 USD
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
835000 USD
CY2015 bcli Exercise And Reissuance Of Warrants Value
ExerciseAndReissuanceOfWarrantsValue
12409000 USD
CY2015 bcli Exercise Of Liability Classified Warrants
ExerciseOfLiabilityClassifiedWarrants
145000 USD
CY2015 bcli Exercise Of Equity Classified Warrants
ExerciseOfEquityClassifiedWarrants
2333000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000 USD
CY2015 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2000 USD
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.0833 pure
CY2015Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
607000 USD
CY2014Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
962000 USD
CY2015Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
152000 USD
CY2014Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
43000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
271000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
313000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1568000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1524000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1297000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1211000 USD
CY2015 us-gaap Depreciation
Depreciation
87000 USD
CY2014 us-gaap Depreciation
Depreciation
106000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
54000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
55000 USD
CY2014 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
1344000 USD
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
34672000 USD
CY2014Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
29222000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11778000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10994000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11778000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10994000 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2842000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3789000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5646000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5457000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8488000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9246000 USD
CY2015 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
161000 USD
CY2014 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
164000 USD
CY2014Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-15
CY2015 bcli Amounts Of Grants Received
AmountsOfGrantsReceived
1763000 USD
CY2015 bcli Grants Underlying Basis
GrantsUnderlyingBasis
The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -27.75pt; MARGIN: 0in 0in 0pt 112.8pt" align="justify"></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.7pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="76"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28.35pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="38"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> B.</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of estimates:</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4 bcli Share Based Goods And Non Employee Services Transaction Securities Outstanding Weighted Average Issue Price
ShareBasedGoodsAndNonEmployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice
4.02
CY2015 bcli Share Based Goods And Nonemployee Services Transaction Weighted Average Issue Price Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionWeightedAverageIssuePriceOfSecuritiesIssued
3.94
CY2015Q4 bcli Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number
ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber
891197 shares
CY2014Q4 bcli Share Based Goods And Non Employee Services Transaction Securities Outstanding Weighted Average Issue Price
ShareBasedGoodsAndNonEmployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice
4.07
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1002451 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
792110 shares
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M5D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
611761 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
331500 shares
CY2014Q4 bcli Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number
ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber
863786 shares
CY2013Q4 bcli Share Based Goods And Nonemployee Services Transaction Securities Outstanding Number
ShareBasedGoodsAndNonemployeeServicesTransactionSecuritiesOutstandingNumber
840367 shares
CY2015 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
27411 shares
CY2014 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
23419 shares
CY2014 bcli Share Based Goods And Nonemployee Services Transaction Weighted Average Issue Price Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionWeightedAverageIssuePriceOfSecuritiesIssued
4.91
CY2015Q4 bcli Share Based Goods And Non Employee Services Transaction Securities Outstanding Weighted Average Issue Price
ShareBasedGoodsAndNonEmployeeServicesTransactionSecuritiesOutstandingWeightedAverageIssuePrice
4.07
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
943000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1222000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
292000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
333000 USD
CY2015 bcli Corporate Effective Income Tax Rate
CorporateEffectiveIncomeTaxRate
0.35 pure
CY2014 bcli Corporate Effective Income Tax Rate
CorporateEffectiveIncomeTaxRate
0.35 pure

Files In Submission

Name View Source Status
0001144204-16-086932-index-headers.html Edgar Link pending
0001144204-16-086932-index.html Edgar Link pending
0001144204-16-086932.txt Edgar Link pending
0001144204-16-086932-xbrl.zip Edgar Link pending
bcli-20151231.xml Edgar Link completed
bcli-20151231.xsd Edgar Link pending
bcli-20151231_cal.xml Edgar Link unprocessable
bcli-20151231_def.xml Edgar Link unprocessable
bcli-20151231_lab.xml Edgar Link unprocessable
bcli-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tex10-11pg4a.jpg Edgar Link pending
tex10-11pg4b.jpg Edgar Link pending
tex10-11pg4c.jpg Edgar Link pending
tex10-12sealb.jpg Edgar Link pending
tseal.jpg Edgar Link pending
v432184_10k.htm Edgar Link pending
v432184_ex10-11.htm Edgar Link pending
v432184_ex10-12.htm Edgar Link pending
v432184_ex10-53.htm Edgar Link pending
v432184_ex21.htm Edgar Link pending
v432184_ex23-1.htm Edgar Link pending
v432184_ex31-1.htm Edgar Link pending
v432184_ex31-2.htm Edgar Link pending
v432184_ex32-1.htm Edgar Link pending
v432184_ex32-2.htm Edgar Link pending